For CML, current therapeutic strategies to prevent the proliferation of cancer cells and activate subsequent apoptosis are to use of tyrosine kinase inhibitors (TKIs), which inhibit BCR-ABL phosphorylation (Nowell and Hungerford, 1960; Kabarowski and Witte, 2000; O'Dwyer, 2002; Okuda et al., 2001). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.